PYXIS ONCOLOGY INC

Interim CEO Civik Thomas buys 250k shares after Pyxis Oncology’s $50 M financing, signaling confidence in accelerated cancer‑drug development and potential investor upside.

Dupont Jakob’s Rule 10b5‑1 trades at Pyxis Oncology show disciplined buying‑options‑selling‑shares strategy, signaling insider confidence in the company’s oncology growth.

Insider buys 109k Pyxis Oncology shares & options: a bullish signal that top execs see value amid market volatility, hinting at future upside.

Pyxis Oncology insider buying surge shows exec confidence but no big price jump; investors should watch vesting, clinical milestones and dilution risks.

Insider buys 45,867 Pyxis Oncology options for free—signaling confidence in a rebounding pipeline and potential price lift beyond the 52‑week low.

Pyxis Oncology insider sales signal caution amid volatility, with directors selling shares below market while executives buy options, hinting at mixed investor sentiment.

Pyxis Oncology’s CEO exercises zero‑price options, signaling confidence and long‑term commitment to new therapies and potential upside for investors.